The FDA has significantly eased regulatory constraints on CAR T-cell therapies used for blood cancers like leukemia and lymphoma. The agency eliminated the Risk Evaluation and Mitigation Strategies (REMS) previously required to manage potentially life-threatening side effects such as cytokine release syndrome and neurotoxicity, citing accumulated clinical experience and stable adverse event rates. This regulatory shift is expected to broaden patient access and reduce administrative burdens for healthcare providers, benefiting therapies from manufacturers including Novartis, Gilead Sciences, Bristol Myers Squibb, and Johnson & Johnson.